Official Title
Incidence of Thromboembolic Events and Prognosis of COVID-19 Patients Hospitalized in Intensive Care Units in France
Brief Summary

The main objective of this study is to describe the incidence of thromboembolic events in a population of patients hospitalized in intensive care units in France for severe COVID-19. The secondary objective of this study is to describe the evolution of hemostasis parameters during the first two weeks of intensive care hospitalization and to evaluate the influence of different anticoagulation regimens on these parameters and on the incidence of thromboembolic events

Unknown status
Pulmonary Thromboembolism
Eligibility Criteria

Inclusion Criteria:

- Confirmed infection with the Sars-CoV-2 virus (RT-PCR)

- Hospitalization in Intensive Care Unit

- Age over 18 years Old

Exclusion Criteria:

- Refusal of the patient to participate in data collection

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
France
Locations

Service d'Anesthésie-Réanimation - Nouvel Hôpital Civil
Strasbourg, France

Investigator: Charles TACQUARD, MD
Contact: 33 3 69 55 16 08
charlesambroise.tacquard@chru-strasbourg.fr

Investigator:

Contacts

Charles TACQUARD, MD
33 3 69 55 16 08
charlesambroise.tacquard@chru-strasbourg.fr

Saïd CHAYER, PhD, HDR
33 3 88 11 66 90
said.chayer@chru-strasbourg.fr

University Hospital, Strasbourg, France
NCT Number
Keywords
Covid-19
thrombosis
D-Dimers
anticoagulation
MeSH Terms
COVID-19
Pulmonary Embolism
Thromboembolism